Varicella-zoster virus and hepatitis B virus reactivations have been reported after starting interferon-free direct-acting antiviral agent (DAA) combinations. HIV/HCVcoinfected patients could be a high-risk group for the reactivation of latent infections. Because of these, we report the occurrence of severe infections after starting DAA regimens in HIV/HCV-coinfected patients. Individuals included in the HEPAVIR-DAA (NCT02057003) cohort were selected if they had received all-oral DAA combinations. A retrospective review of clinical events registered between the start of DAAs and 12 months after SVR12 was carried out. Overall, 38 (4.5%) of 848 patients presented infections. The incidence (95% confidence interval) of infections was 4.6 
Summary
Varicella-zoster virus and hepatitis B virus reactivations have been reported after starting interferon-free direct-acting antiviral agent (DAA) combinations. HIV/HCVcoinfected patients could be a high-risk group for the reactivation of latent infections. Because of these, we report the occurrence of severe infections after starting DAA regimens in HIV/HCV-coinfected patients. Individuals included in the HEPAVIR-DAA (NCT02057003) cohort were selected if they had received all-oral DAA combinations. A retrospective review of clinical events registered between the start of DAAs and 12 months after SVR12 was carried out. Overall, 38 (4.5%) of 848 patients presented infections. The incidence (95% confidence interval) of infections was 4.6 (3.3-6.3) cases per 100 person-years. The median (Q1-Q3) time to the infection since baseline was 23 (7.3-33) weeks. Five (13%) of the patients with infections died; four of them had cirrhosis. The frequency of previous AIDS was 21 (54%) for patients with infections and 324 (40%) for those without infections (P = 0.084). The median (Q1-Q3) nadir CD4 cell count of individuals with and without infections was 75 (53-178) and 144 (67-255) cells/μL, respectively (P = 0.047). Immunodepression-associated infections were observed in 9 (1.1%) patients. All of them had suppressed HIV replication with antiretroviral therapy. In conclusion, severe infections are relatively common among HIV/HCV-coinfected patients receiving all-oral DAA combinations.
Some unusual reactivations of latent infections in patients with suppressed HIV replication seem to be temporally linked with DAA use. 
| INTRODUC TI ON

| PATIENTS AND ME THODS
| Design
| Classification of infections
| Follow-up
Patients were prospectively evaluated at the date of starting DAA therapy and at least week 4 and 12 of treatment. After the scheduled end of therapy, patients were evaluated at week 12 post-treatment. The period of observation between SVR12 and 12 months afterwards was retrospectively reviewed using clinical records. HIV-infected patients were followed up at least every 24 weeks at the participating units. SVR12 was defined as undetectable plasma HCV RNA 12 weeks after the scheduled end of therapy.
| Statistical analysis
The incidence of infections was calculated for the study period. The baseline date was the date starting DAA therapy, and the end of followup was 12 months after SVR12. For controls, the baseline date was the first visit within the period of inclusion and the end of follow-up was 
K E Y W O R D S
direct-acting antivirals, HCV, HIV, immunodepression-related infections
| Ethics
The study was carried out according to the Helsinki Declaration and was approved by the local Ethics Committee. All patients gave their written informed consent to participate in the study cohort. 
| RE SULTS
| Characteristics of the study population
| Incidence of infections
During the period of observation, 38 (4.5%) patients suffered from infections. The baseline characteristics of these patients were not significantly different from those who did not develop infections, but for nadir CD4 cell counts and the proportion of subjects with previous AIDS diagnosis ( Table 1 ). The global incidence of infections was 4.6 (3.3-6. 
| Description of infections
Five (13%) patients with infections died during the study period; four of them had cirrhosis. In four individuals, there was an early onset of infection, before finishing anti-HCV treatment.
Nine individuals showed immunodepression-related infections ( Table 2 This study may have some limitations. First, this was a retrospective study, in which clinical records were reviewed to obtain data on events registered during a part of the follow-up.
As such, some cases could have been missed and the incidence of events might have been underestimated. This is unlikely for immunodepression-related infections and severe bacterial infections, as severe outcomes, many of them requiring admission, are not easily overlooked. In addition, most HIV-infected patients are linked to tertiary care in Spain. They follow scheduled clinical visits, and in case of adverse outcomes, they usually seek medical attention at their infectious diseases unit. Second, we were able to compare the incidence of events reported herein with that of a control group of HIV-infected patients. However, the incidence of some minor non-AIDS events might have not been recorded in some cases, which might have led to an underestimation of the incidence of less severe infections in the control group.
Comparisons with other studies are difficult because differences in key risk factors with the populations included in the studies where these data have been analysed preclude drawing reliable conclusions. 
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